PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. [electronic resource]
Producer: 20180206Description: 523-535 p. digitalISSN:- 1557-3265
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Benzimidazoles -- administration & dosage
- Cell Line, Tumor
- Cisplatin -- administration & dosage
- Dacarbazine -- administration & dosage
- Drug Synergism
- Etoposide -- administration & dosage
- Gene Expression Regulation, Neoplastic -- drug effects
- Genomics -- methods
- Humans
- Indoles -- administration & dosage
- Mice
- Nuclear Proteins -- genetics
- Phthalazines -- administration & dosage
- Piperazines -- administration & dosage
- Poly (ADP-Ribose) Polymerase-1 -- antagonists & inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors -- administration & dosage
- Small Cell Lung Carcinoma -- drug therapy
- Temozolomide
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.